bioRxivMicrobiology
Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects
S. Lusvarghi, W. Wang, R. Herrup, S. N. Neerukonda, R. Vassell, L. Bentley, A. E. Eakin, K. J. Erlandson, C. D. Weiss
Abstract
Mutations in the spike protein of SARS-CoV-2 variants can compromise the effectiveness of therapeutic antibodies. Most clinical-stage therapeutic antibodies target the spike receptor binding domain (RBD), but variants often have multiple mutations in several spike regions. To help predict antibody potency against emerging variants, we evaluated 25 clinical-stage therapeutic antibodies for neutralization activity against 60 pseudoviruses bearing spikes with single or multiple substitutions in several spike domains, including the full set of substitutions in B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), A.23.1 and R.1 variants. We found that 14 of 15 single antibodies were vulnerable to at least one RBD substitution, but most combination and polyclonal therapeutic antibodies remained potent. Key substitutions in variants with multiple spike substitutions predicted resistance, but the degree of resistance could be modified in unpredictable ways by other spike substitutions that may reside outside of the RBD. These findings highlight the importance of assessing antibody potency in the context of all substitutions in a variant and show that epistatic interactions in spike can modify virus susceptibility to therapeutic antibodies. ImportanceTherapeutic antibodies are effective in preventing severe disease from SARS-CoV-2 infection (COVID-19), but their effectiveness may be reduced by virus variants with mutations affecting the spike protein. To help predict resistance to therapeutic antibodies in emerging variants, we profiled resistance patterns of 25 antibody products in late stages of clinical development against a large panel of variants that include single and multiple substitutions found in the spike protein. We found that the presence of a key substitution in variants with multiple spike substitutions can predict resistance against a variant, but that other substitutions can affect the degree of resistance in unpredictable ways. These finding highlight complex interactions among substitutions in the spike protein affecting virus neutralization and potentially virus entry into cells.
- organism: virus
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Y. Weisblum, F. Schmidt, … P. D. Bieniasz·bioRxiv·Jul 21, 2020
- The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants
E. Makdasi, A. Zvi, … R. Rosenfeld·bioRxiv·Apr 1, 2021
- SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity
S. N. Neerukonda, R. Vassell, … W. Wang·bioRxiv·Nov 5, 2021
- Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
C. Graham, J. Seow, … K. J. Doores·bioRxiv·Feb 3, 2021
- The impact of Spike mutations on SARS-CoV-2 neutralization
C. Rees-Spear, L. Muir, … L. E. McCoy·bioRxiv·Jan 15, 2021
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
P. Wang, M. S. Nair, … D. D. Ho·bioRxiv·Jan 25, 2021